| Title |
PARP inhibitors in the management of breast cancer: current data and future prospects
|
|---|---|
| Published in |
BMC Medicine, August 2015
|
| DOI | 10.1186/s12916-015-0425-1 |
| Pubmed ID | |
| Authors |
Luca Livraghi, Judy E. Garber |
| Abstract |
Poly(ADP-ribose) polymerases (PARP) are enzymes involved in DNA-damage repair. Inhibition of PARPs is a promising strategy for targeting cancers with defective DNA-damage repair, including BRCA1 and BRCA2 mutation-associated breast and ovarian cancers. Several PARP inhibitors are currently in trials in the adjuvant, neoadjuvant, and metastatic settings for the treatment of ovarian, BRCA-mutated breast, and other cancers. We herein review the development of PARP inhibitors and the basis for the excitement surrounding these agents, their use as single agents and in combinations, as well as their toxicities, mechanisms of acquired resistance, and companion diagnostics. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Belgium | 1 | 13% |
| United States | 1 | 13% |
| United Kingdom | 1 | 13% |
| Unknown | 5 | 63% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 324 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | <1% |
| India | 1 | <1% |
| Slovenia | 1 | <1% |
| Unknown | 320 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 53 | 16% |
| Student > Bachelor | 51 | 16% |
| Student > Master | 49 | 15% |
| Researcher | 48 | 15% |
| Other | 23 | 7% |
| Other | 45 | 14% |
| Unknown | 55 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 78 | 24% |
| Biochemistry, Genetics and Molecular Biology | 70 | 22% |
| Agricultural and Biological Sciences | 66 | 20% |
| Pharmacology, Toxicology and Pharmaceutical Science | 18 | 6% |
| Chemistry | 7 | 2% |
| Other | 26 | 8% |
| Unknown | 59 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 49. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 December 2023.
All research outputs
#755,336
of 23,323,574 outputs
Outputs from BMC Medicine
#528
of 3,508 outputs
Outputs of similar age
#10,283
of 265,462 outputs
Outputs of similar age from BMC Medicine
#17
of 87 outputs
Altmetric has tracked 23,323,574 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,508 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 43.8. This one has done well, scoring higher than 84% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 265,462 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.